Dyne Therapeutics (DYN) Projected to Announce Quarterly Earnings on Monday

Dyne Therapeutics (NASDAQ:DYN) is projected to post its Q2 2026 results before the market opens on Monday, July 27th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 9:30 AM ET.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter last year, the business earned ($1.05) earnings per share. On average, analysts expect Dyne Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dyne Therapeutics Stock Performance

DYN stock opened at $24.44 on Friday. The stock has a market cap of $4.05 billion, a P/E ratio of -7.59 and a beta of 1.06. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The firm has a 50 day simple moving average of $20.38 and a 200 day simple moving average of $18.62. Dyne Therapeutics has a 52 week low of $8.88 and a 52 week high of $25.00.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DYN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, July 6th. Evercore set a $33.00 price target on Dyne Therapeutics in a research report on Friday, May 15th. Sanford C. Bernstein raised their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Finally, TD Cowen began coverage on Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Insider Transactions at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 480,240 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $22.79, for a total transaction of $10,944,669.60. Following the sale, the director owned 875,912 shares of the company’s stock, valued at $19,962,034.48. This trade represents a 35.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders bought 9,000 shares of company stock valued at $156,800 and sold 2,066,372 shares valued at $43,648,928. Insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently made changes to their positions in DYN. Aster Capital Management DIFC Ltd acquired a new position in Dyne Therapeutics in the 4th quarter valued at about $84,000. Steward Partners Investment Advisory LLC lifted its holdings in Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after purchasing an additional 7,697 shares during the period. Prudential Financial Inc. bought a new stake in Dyne Therapeutics in the 2nd quarter valued at $111,000. Finally, Creative Planning grew its holdings in Dyne Therapeutics by 23.8% in the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after buying an additional 2,797 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.